| Symbol | CAI |
|---|---|
| Name | CARIS LIFE SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 750 W. JOHN CARPENTER FREEWAY,SUITE 800, IRVING, Texas, 75039, United States |
| Telephone | (866) 771-8946 |
| Fax | — |
| — | |
| Website | www.carislifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002019410 |
| Description | Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. Additional info from NASDAQ: |
Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
Read more📋 DAVID SPETZLER (Officer) plans to sell 119K shares of CARIS LIFE SCIENCES, INC. (at $24.76 each, total $3.0M) Filed: Sep 04, 2026 | ID: 009157
Read more📋 DAVID SPETZLER (Officer) plans to sell 478K shares of CARIS LIFE SCIENCES, INC. (at $24.86 each, total $11.9M) Filed: Sep 03, 2026 | ID: 009094
Read moreCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Read moreCaris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Read more📋 GEORGE H POSTE REVOCABLE TRUST (Ex-Affiliate) plans to sell 100K shares of CARIS LIFE SCIENCES, INC. (at $26.06 each, total $2.6M) Filed: Aug 24, 2026 | ID: 008599
Read moreDirector CASTLEMAN PETER M 🟢 acquired 13.2K shares of Caris Life Sciences, Inc. (CAI) Transaction Date: Aug 14, 2026 | Filing ID: 000008
Read moreDirector PHILLIPS T DANNY 🟢 acquired 13.2K shares of Caris Life Sciences, Inc. (CAI) Transaction Date: Aug 14, 2026 | Filing ID: 000005
Read moreDirector Minor Lloyd 🟢 acquired 13.2K shares of Caris Life Sciences, Inc. (CAI) Transaction Date: Aug 14, 2026 | Filing ID: 000007
Read moreDirector Gilliam Joseph E 🟢 acquired 13.2K shares of Caris Life Sciences, Inc. (CAI) Transaction Date: Aug 14, 2026 | Filing ID: 000025
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05692466 | Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Mole… | — | Stage III Solid Tumors | Unknown | 2023-02-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE… | Phase2 | Solid Tumor | Terminated | 2019-03-22 | 2022-01-04 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EORTC QLQ-30 | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05692466 |
| Comprehensive molecular panel test | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05692466 |
| Debio 1347 | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT03834220 |